Overview

Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Tolerability, efficacy and handling of Berodual® Respimat® 20/50µg/dose solution for inhalation in patients with chronic obstructive airways disease in daily practice
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Fenoterol
Fenoterol, ipratropium drug combination
Ipratropium
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

- Men and women presenting with the symptoms of chronic obstructive airways disease were
given Berodual® Respimat® 20/50µg/dose solution for inhalation only where this was
considered necessary in medical terms

- Patients who have not been treated prior to the post-marketing surveillance study as
well as patients who have been treated with Berodual® metered dose inhaler (MDI) or
other respiratory medications prior to the Post-Marketing Surveillance Study could be
included

Exclusion Criteria:

- Patients presenting with the general and specific contraindications listed in the
Patient Information Leaflet and the Basic Product Information